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ABSTRACT 
 
Fingolimod is a novel immunomodulatory drug used in patients with relapsing multiple 
sclerosis (MS) which reversibly inhibits egress of lymphocytes from lymph nodes.  
In this longitudinal study, the frequency of Interferon- gamma (IFN-γ)+, IL4+, IL17+ 
and IL10+ CD4+ and CD8+ T cell subsets were measured in Fingolimod treated patients 
before and after 12 months’(12M) therapy using flow cytometry and compared to those of 
naive, Betaferon treated MS patients and healthy individuals. Additionally, the level of 
transcription factor IRF4 and IL-6, IL-23, TGF-β1 cytokines, required for differentiation of 
IL-17+ T cells, were assessed by RT-PCR and ELISA, respectively.  
In Fingolimod treated MS patients, we observed a significant decrease in the percentage 
of IFN-γ+/IL17+ CD4+ and CD8+ T cell subsets. In contrast, Fingolimod increased 
IL10+ CD4+ T cells. We also showed that IFN-γ+IL17+ co-producing CD8+ T cells were 
reduced in patients under ﬁngolimod therapy. furthermore, Fingolimod could reduce the 
expression level of IRF4 in patients while IL6 was increased in the supernatant of cultured 
peripheral blood mononuclear cells.  
Our data showed that Fingolimod treatment alters CD4+ and CD8+ T cell subsets and 
reduces expression of IRF-4, which affects the proportion of pathogenic memory T cells in 
peripheral blood. 
 
Keywords: Fingolimod; IFN regulatory factor 4; Multiple sclerosis; T cells 
 
INTRODUCTION 
 
Multiple sclerosis (MS) is an immune-mediated 
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individuals.
1
 It has been now determined that in 
addition to Th1 cells, interleukin 17 producing CD4+ 
T (Th17) cells has a pathogenic role in the 
development of MS and its animal model, 
experimental Autoimmune encephalomyelitis 
(EAE).
2-5
 Th1 and Th17 cells exist in MS lesions and 
can promote neurodegeneration and Blood-brain 
barrier (BBB) disruption.
6,7
 A combination of 
several cytokines, including IL-6, TGF-β, IL-23, IL-
1b, and IL-21 stimulate Th17 cell differentiation.
8
 
Some of the Th17 cell clones are able to co-produce 
IL-17 and IFN-γ. These non-classical Th17/Th1 
subsets, which share features of both Th17 and Th1 
cells, may have a particular effector role in the CNS 
inflammation.
9-11
 In addition to Th1 and Th17 cells, 
CD8+ T cells are also suspected to involve in MS 
pathogenesis. Similar to Th cells, CD8+ T cells 
categorize into different subsets based on their 
cytokine proﬁle.12-14 Recently, IL-17 producing 
CD8+ T cells (Tc17) have been found among cells 
infiltrating active lesions, in peripheral blood of 
relapsing-remitting multiple sclerosis (RRMS) 
patients in the relapse phase and Cerebrospinal Fluid 
(CSF) of patients with early-stage MS.
15-18
  
Interferon regulatory factor 4 (IRF-4), a member 
of IRF family of transcription factors, has been 
reported to be necessary for IL-17 induction. IRF-4 
has the essential role in autoimmune disease models 
especially in EAE.
19-22
 IRF4 deficient mice have a 
marked decrease in Th17 cells in the brain.
20
 
Moreover, IRF4 is also required for the 
differentiation of Tc17 cells during CNS 
autoimmunity.
16,20,23
 These data show the importance 
of IRF4 in T-cell differentiation and autoimmune 
diseases. 
Fingolimod (FTY720) is a sphingosine 1-
phosphate (S1P1) receptor antagonist, which was the 
first oral drug for the treatment of RRMS.
24,25
 
Binding of fingolimod to S1P1 receptors, causes their 
internalization and degradation, which retains T and 
B lymphocytes within secondary lymphoid organs 
(SLOs).
26-28
 This drug selectively retains CC-
chemokine receptor 7 (CCR7)
 
positive naive and T 
central memory (TCM) cells including autoreactive 
Th17 cells within lymphoid nodes, but not CCR7
 
negative T effector memory (TEM) cells and affects 
CD8 T cells less.
29-32
 Previous studies in 
Fingolimod-treated MS patients showed that the 
frequency and counts of T cell subsets changed in 
circulation, including a decrease in naïve and TCM 
cells and an increase of TEM and memory regulatory 
CD4+ T (Treg) cells.
29,30,33,34
 fingolimod also 
reduces the percentage of memory B cells but 
increases naïve and transitional B cells, plasma cells 
and regulatory B cell subsets.
32
 Additionally, the 
frequency of CD56 bright natural killer cells was 
reduced after Fingolimod therapy.
35
 However, there 
are a few studies investigating the effect of 
fingolimod on the frequency of CD8+ and CD4+ T 
cells subsets in MS patients, which are different in 
drug dosage and study duration. A study  showed a 
decrease in the percentage of IL17+ CD4+ and IFN-
γ+ CD8+ T cells in patients after 1-month 
fingolimod therapy.
36
 In a recent study, the 
percentages of both CD4+ and CD8+ IFN-γ 
producing T cells as well as IL17+CD4+ T cells 
increased transiently 2 weeks after initiation of 
fingolimod and then decreased gradually after 3 
months.
33
 A study reported  that Fingolimod (1.25 
mg /day) could reduce the frequency of IL17+ CD4+ 
T cells in MS patients at long-term therapy.
30
 While  
other study showed an increase in circulating Th17 
cells in half of patients after short-term therapy with 
less dosage of Fingolimod (0.5 mg/day).
37
 These 
results indicate some controversy among studies 
which makes essential the further evaluation of 
Fingolimod treatment on cytokine-producing T cell 
subsets at a usual dose (0.5mg/day) in a long-term 
treatment. 
Here we examined the effect of Fingolimod on 
frequency of CD4+ and CD8+ T cells subsets 
including Th1, Th2, Th17, Th10, Th1/17 and Tc1, 
Tc2, Tc17, Tc10, Tc1/17. We also evaluated IL-6, 
IL-23 and TGF-β1, necessary cytokines for induction 
of IL-17 producing CD4+ and CD8+ T cells,  
in patients  under Fingolimod therapy in a 12 months 
follow-up study. We also provide new evidence  
of the effect of Fingolimod on the expression of IRF-
4. 
 
MATERIALS AND METHODS 
 
Patients and Control Subjects 
A total of 45 Relapsing remitting (RR) MS 
patients were involved in this study, including 10 
treatment-naive MS patients, 15 MS patients on 
Interferon-β (IFN-β) treatment and 20 MS patients 
on fingolimod treatment (0.5 mg/once a day). A 
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longitudinal follow-up study was performed on 
patients initiating fingolimod drug. IFN-β treated MS 
patients had an average treatment of 5.8 years equal to 
average disease duration. Treatment-naive MS 
Patients were not under any immunosuppressive or 
immunomodulatory treatments at least 3 months 
before the sampling. All MS patients were diagnosed 
according to the revised McDonald criteria at the MS 
research center of Sina General Hospital, Tehran.
38
 
Disability was assessed by an experienced neurologist 
using expanded disability status scale (EDSS). Fifteen 
age-matched healthy volunteers who had no history of 
MS or other autoimmune diseases in their families were 
also participants in this research. All patients and 
controls were Iranian Caucasian origin.   
 
Cell Preparation and Culture 
Peripheral blood mononuclear cells (PBMCs) were 
isolated by density gradient centrifugation over 
Lymphodex (innoTrain, Germany). 10
6
 cells/mL were 
cultured in RPMI 1640 (Sigma-Aldrich, US) 
supplemented with penicillin (100 IU/mL), 
streptomycin (100 µg/mL), 1% L-glutamine 100 mM 
and 10% fetal calf serum (Gibco, US). Cells were 
stimulated with anti-CD3 (1 mg/mL; Mabtech, 
Sweden) and anti-CD28 (0.1mg/mL; Mabtech, 
Sweden) monoclonal antibodies (mAbs). The cells 
were incubated in 5% CO2, at 37°C. After 66h, the 
supernatants (SNs) were collected and stored in -70°c 
until the cytokine measurements and the cells were 
additionally incubated in the presence of phorbo-12-
myristate-13-acetate (PMA 50 ng/ml, Sigma-Aldrich, 
US), ionomycin (500 ng/ml, Sigma-Aldrich, US) and 
Golgi Plug (1 μl/10 6 cells, BD Biosciences, US) for 6h. 
After incubation time cells were harvested for flow 
cytometric analysis.
18
 
 
Multicolor Flow Cytometry Assay 
To analyze the frequency of CD4+ and CD8+ T cell 
subsets, the harvested cells were washed once with PBS 
and after staining evaluated by flow cytometry. In brief, 
the 10
6
 cells/100ul staining buffer (PBS+2% FCS) were 
first stained for surface antigens with anti-CD4-APC-
eflour780 and CD8-PerCP-cyanin5.5 (BioLegend, US) 
monoclonal antibodies for 30 minutes in the dark at 4°C 
and then the cells were fixed and permeabilized with 
Cytofix/Cytoperm (BIO-RAD, BUF09B, US) according 
to the manufacturer’s instructions. Intracellular cytokine 
staining was performed using anti-IFN-γ-PE-CY-7, IL-
17-FITC, IL-4-APC (BD Biosciences, US) and IL-10-PE 
(BioLegend, US) monoclonal antibodies. The stained 
cells were analyzed with a FACS Aria II flow cytometer 
(BD Biosciences, US) using FACSDiva software. 
 
Cytokine Measurement 
For analysis of Th17 and Tc17 polarization 
cytokines, IL-6, IL-23 (eBioscience, CA) and TGF-β1 
(Mabtech, Sweden), were measured in the supernatant 
of stimulated cells by commercial ELISA kits 
following the manufacturer’s recommendations. The 
detection limits of the studied cytokines were 2 pg/mL 
for IL-6, 10 pg/mL for IL-23, and 10.4 pg/mL for TGF- 
β1. 
 
Quantitative Real-time PCR (qPCR) 
Total RNA was isolated from PBMCs using RNX 
plus (RN7713C) according to the manufacturer’s 
instructions. To eliminate any residual genomic DNA 
from the sample, extracted RNAs were treated with 
RNase-free DNase I (Invitrogen Life Technologies). 
Reverse transcription into cDNA was performed with 
cDNA synthesis kit (fermentase, lithuania). Real-time 
PCR analysis for quantiﬁcation of expression of IRF-4 
was performed with EvaGreen PCR Master Mix plus 
(ROX) (Solis BioDyne, Tartu, Estonia) on a Light 
Cycler 480II (Applied Biosystems, US) according to 
the manufacturer’s recommendations. Relative 
expression level of IRF-4 was normalized by GAPDH 
as a house housekeeping gene and calculated by the 
2
_ΔΔCt
 method.
39
 The data were presented as fold 
change relative to control samples.  
The sequences of the primers in the 5´ to 3´ 
direction were as follows: IRF4 forward: 5´-AG-CGC-
ATT-TCA-GTA-AAT-GTA-AAC-ACA-T-3´ and 
IRF4 reverse: 5´-TCT-TGT-GTT-CTG-TAG-ACT-
GCC-ATC-A-3´, GAPDH forward: 5'-TCT-TTT-GCG-
TCG-CCA-GCC-GA-3' and GAPDH reverse: 5'-AGT-
TAA-AAG-CAG-CCC-TGG-TGA-CCA-3'. 
 
Statistical Analysis 
Statistical analysis was performed using SPSSv23 
(SPSS Inc; Chicago, IL, USA). Paired T-test or non-
parametric Wilcoxon signed-rank test was used to 
compare results of experiments before and 12 months 
after ﬁngolimod therapy according to the normality of 
the data as assessed by Kolmogorov-Smirnov/Shapiro-
Wilk test. The comparisons between multiple groups 
were performed using one-way ANOVA with Welch’s 
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correction and Tukey’s multiple comparison post-hoc 
test. Pearson correlation was used for correlation 
assessment unless the data were not normally 
distributed, in which case Spearman correlation 
analysis was performed. A p-value less than 0.05 was 
considered signiﬁcant. The figures were drawn using 
GraphPad Prism, Version 6.00 software. 
 
 
Ethical Considerations 
This work supported by Tehran university of 
medical sciences [94.01.30,27866]. The study was 
conformed to the Helsinki declaration and approved by 
the Ethics Committee of the Tehran University of 
Medical Sciences. Written informed consent was 
obtained from all patients and healthy controls. 
 
 
 
Figure 1. Representative gating strategy for different CD4+ and CD8+ T cell subsets. In this sample gating, cells were first 
gated for lymphocytes (SSC-A vs. FSC-A). The lymphocyte gate was further analyzed for IFN-γ, IL-4, IL-17, IL-10 and IFN-
γ/IL-17 CD4 and CD8 positive cells fractions. 
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Table 1. Clinical Characteristics of Study Population 
Group 
Gender 
EDSS ( range) 
agea (range) F/M Disease duration(years) 
Total ( n=60) 31 (19-52) 42/18 5.6 (1-20) 1.9 (0.5-4) 
Treatment naive ( n=10) 30 (25-52) 8/2 2.5 (1-6) 1.6 (1-2.5) 
Betaferon ( n=15) 33 (23-49) 11/4 5.8 (1-19) 1.7 (1-3) 
b Fingolimod ( n=20) 29 (19-43) 15/5 7.2 (2-20) 2.06 (0.5-3.5) b 
C Fingolimod (n=16) 30 (20-44) 11/5 5.9 (3-21) 2.2 (0.5-4) c 
Healthy control ( n=15) 30 ( 23-43) 8/7   
a. Mean age in years.   b. Before Fingolimod initiation 
c. After Fingolimod initiation  Data are expressed as mean (range). 
Abbreviations: F = female; M = male; EDSS= expanded disability status scale 
 
 
RESULTS 
 
A total of 60 study population were recruited in this 
study. A longitudinal follow-up study was performed 
on 20 patients under Fingolimod therapy.  
The patients were in remission and discontinued the 
other immunomodulatory drugs for wash-out of the 
previous therapies, almost 3 weeks before ﬁngolimod 
initiation They did not have any relapse during therapy. 
(Descriptive and clinical characteristics of Fingolimod-
treated MS patients and controls are presented in Table 
1. Four Fingolimod-treated patients did not finish the 
study due to side effects caused by the treatment and 
pregnancy. Different groups of controls were recruited 
in this study to compare the percentage of cell subsets 
between controls and patients before and after 
Fingolimod therapy to confirm the validity that shows 
the previous treatment was not probably effective. 
For flow cytometry analysis, lymphocytes were first 
gated on a forward vs. side scatter dot plot. Then, 
CD4+ and CD8+ subsets were determined on gated 
cells. Post-acquisition analysis was done using the 
Flow Jo software package v.7.6.1 (Tree Star). At least 
50,000 events were acquired within the cultured cells. 
A representative example of gating strategy is 
illustrated in Figure 1. 
 
Fingolimod Therapy Alters CD4+ and CD8+ T Cell 
Frequencies in Peripheral Blood with A Decreased 
CD4/CD8 T Cell Ratio 
The mean percentage of CD4+ T lymphocytes was 
reduced in Fingolimod-treated MS patients after 12 
months therapy (9.77%) compared to baseline 
(35.23%), treatment naïve (36.32%), Betaferon treated 
(32.23%) MS patients and healthy individuals (32.45%) 
(p<0.0001). The frequency of CD8+ T lymphocytes 
also decreased in Fingolimod-treated MS patients after 
12M therapy (21.75%) compared to baseline (28.31%) 
(p<0.05), treatment-naïve (26.04%), Betaferon treated 
(24.72%) MS patients and healthy individuals (23.75%) 
(Table 2).  
We also compared the CD4/CD8 T cells ratio 
between studied groups. We found a reduction of the 
CD4/CD8 T cells ratio in patients under Fingolimod 
therapy (0.522) in comparison with baseline (1.366, 
p<0.0001), treatment naive (1.41, p<0.01), Betaferon 
treated (1.40, p<0.0001) MS patients and healthy 
individuals (1.39, p<0.0001) (Table 2).   
 
Fingolimod Reduces IL-17 and IFN-γ and Increases 
IL-10 Producing CD4+ T Cells in Peripheral Blood 
To characterize the influence of Fingolimod 
treatment on cytokine-producing CD4+ T cell subsets, 
we determined the percentages of IFN-γ, IL-4, IL-17, 
IL-10 cytokine producing CD4+ T helper cells (Th1, 
Th2, Th17 and Th10 respectively) and IFN-γ/IL17 co-
producing cells as a non-classical T cell subset in 
PBMCs of Fingolimod-treated MS patients and 
controls.  
The frequency of IFN-γ and IL-17 producing CD4+ 
T cells from Fingolimod-treated MS patients after 12M 
decreased compared to baseline in total lymphocytes 
(0.236% vs. 0.698 and 5.63% vs. 25.53 respectively, 
p<0.0001) (Figure 2A-B). In addition, we observed an 
increase in frequency of IL-10 secreting CD4+ cells 
after Fingolimod-therapy (0.312% vs. 0.193, p=0.043), 
while there was no difference between the mean 
percentage of IL-4 and IFN-γ/IL17 co-producing CD4+ 
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T cells before Fingolimod initiation and after therapy 
(p>0.05) (Figure 2, C-D-E).  
Fingolimod treated patients after therapy had lower 
IFN-γ+ CD4+ T cells while, pre-treated Fingolimod 
and treatment naïve MS patients had a higher 
percentage compared to healthy controls (p<0.0001, 
p=0.02, p=0.003 respectively) (Figure 3 A). In 
addition, IL-4+ CD4+ T cells decreased in Fingolimod-
treated compared to betaferon treated MS patients 
(p=0.0018) (Figure 3 B). The percentage of IL17+ 
CD4+ T cells also were lower in Fingolimod-treated 
than Betaferon treated and treatment-naive MS patients 
(p=0.001, p<0.0001; respectively) (Figure 3C). 
Furthermore, the percentage of IFN-γ/IL17 co-
producing CD4+ T cells in Fingolimod-treated patients 
before therapy and treatment naïve MS patients were 
higher than healthy controls (p=0.02, p=0.01; 
respectively) (Figure 3E). 
 
Fingolimod Treatment Decreases the Frequency of 
IFN-γ and IL-17 as Well as IFN-γ/IL17 Co-
producing CD8+ T Cells 
To characterize the Effects of Fingolimod treatment 
on cytokine-producing CD8+ T cell subsets, we 
determined the percentages of IFN-γ, IL-4, IL-17, IL-
10 cytokine producing CD8+ T cells (Tc1, Tc2, Tc17 
and Tc10 respectively) and IFN-γ/IL17 co-producing 
cells as a non-classical T cell subset in PBMCs from 
Fingolimod-treated MS patients and controls. 
The percentage of IFN-γ and IFN-γ/IL-17 co-
producing CD8+ T cells decreased after Fingolimod 
therapy compared to the baseline in total lymphocyte 
population (20.52% vs. 35.49%, p=0.001 and 0.314% 
vs. 0.437%, p=0.03, respectively) (Figure. 4 A and E), 
whereas no significant alterations in IL-4 and IL-10 
secreting CD8+ T cells were observed (p=0.46 and 
p=0.08, respectively). In addition, the percentage of 
IL17+ CD8+ T cells was lower in Fingolimod treated 
patients compared to baseline (0.31% vs. 0.51%, 
p=0.009) (Figure 4B). 
The percentage of IFN-γ+ CD8+ T cells in 
Fingolimod-treated patients after therapy was lower 
than treatment naïve MS patients (p=0.001) and higher 
than healthy controls (p=0.004) (Figure 5A). Also, the 
percentages of IL-17+ CD8+ T cells were lower in 
Fingolimod-treated than treatment naïve MS patients 
(p=0.03) (Figure 5 C). Furthermore, the percentages of 
IFN-γ/IL-17 co-producing CD8+ T cells in 
Fingolimod-treated patients before and after therapy 
and treatment naïve MS patients were higher than 
healthy controls (p<0.0001, p=0.002, p=0.0004; 
respectively) (Figure 5E). 
 
Fingolimod Therapy Reduces the Expression of 
Transcription Factor IRF4  
We evaluated the inﬂuence of Fingolimod on 
mRNA expression level of IRF-4, an essential 
transcription factor involved in Th cell differentiation, 
specifically Th17 cells. Our data revealed that the 
mRNA expression level of IRF-4 decreased in 
Fingolimod-treated patients compared to baseline 
(Before initiation) (p=0.02) (Figure 6A). Healthy 
controls (HCs) had the lowest mRNA levels 
(Mean=0.92), and the highest mRNA level was found 
in treatment-naive MS patients (Mean=25.76) (Figure 
6B). Fingolimod-treated patients showed decreased 
expression levels compared to treatment naive MS 
patients (p= 0.04). Furthermore, the expression level of 
IRF-4 in Fingolimod-treated patients before therapy 
and treatment naïve MS patients were higher than 
healthy controls (p<0.0001, p=0.029, respectively) 
(Figure 6B). There was no significant correlation 
between the expression level of IRF-4 and frequency of 
Th17 or Tc17 cells in Fingolimod-treated patients and 
all different groups as well. Interestingly, we have seen 
an increase in expression of IRF-4 in two cases after 
Fingolimod treatment and sought their results of T cell 
subsets and cytokines. In both patients, the levels of IL-
6 and IL-23 cytokines and EDSS score were high after 
Fingolimod treatment. In the patient with very high 
IRF-4 expression, the percentages of CD4+ T cells and 
IFN-γ+ CD8+ T cells was higher than the other cases in 
Fingolimod-treated group. 
 
Fingolimod Treatment Alters Th17 Cell 
Differentiating Cytokines 
We analyzed the levels of several cytokines 
involved in 17+ T cell differentiation including IL-6, 
IL-23, and TGF-β1 in culture supernatants. Our results 
showed an elevated level of IL-6 in Fingolimod-treated 
MS patients after 12M therapy in comparison with 
baseline (p=0.03), while the increase in TGF-β1 and 
IL-23 did not reach signiﬁcance (Figure 7A). Betaferon 
treated patients had reduced concentrations of IL-23 
cytokine in comparison to treatment naïve and 
Fingolimod-treated MS patients (p=0.04 and p=0.036, 
respectively) (Figure 7B). Concentrations of TGF-β1 
cytokine in Fingolimod-treated and betaferon treated 
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MS patients significantly increased compared to 
healthy individuals (p=0.046 and p=0.04, respectively) 
(Figure 7B). We also investigated the associations 
between IRF-4 and IL-6, IL-23 and TGF-β1 cytokines. 
However, we observed no association between the 
expression level of IRF-4 and those of cytokines in 
Fingolimod-treated patients and all different groups. 
 
 
 
 
 
Figure 2. Fingolimod therapy alters the frequency of cytokine producing CD4+ T cell subsets. The percentages of IFN-γ, 
IL17, IL4, IL-10 and IFN-γ/IL17 cytokine producing CD4+ T cells in multiple sclerosis (MS) patients before starting 
Fingolimod (Baseline) and 12-months after therapy (FTY(12M)). Histogram ﬁgures represent mean ±S.E.M. *p<0.05, 
***p<0.0001.   
 
 
 
Table 2. Mean percentage of lymphocyte subsets in peripheral blood of MS patients and controls 
Study Group CD4+ CD8+ CD4+:CD8+ratio 
FTY (12 M) 9.77±3.8 21.75±6.3 0.522±0.34 
FTY (0M) 35.23 ±4.3 28.31±7.6 1.366±0.53 
Betaferon treated 32.23±2.7 24.72±5.8 1.409±0.52 
treatment naive 36.32±4.6 26.04±5.3 1.414±0.25 
HC 32.45±5.2 23.75±3.5 1.397±0.31 
p-value p < 0.0001* p < 0.05* p < 0.0001* 
FTY (0M): before initiation of Fingolimod treatment   FTY (12 M): after 12 months Fingolimod treatment  
HC: healthy controls      Data are expressed as mean± SD.  
* shows signiﬁcant p values which calculated using One-Way ANOVA. 
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Figure. 3 The frequency of cytokine producing CD4+ T cell subsets in multiple sclerosis (MS) patients and healthy controls 
(HC). The percentages of IFN-γ (Th1), IL4 (Th2), IL17 (Th17), IL10 (Th10) producing and IFN-γ/IL17 co-producing CD4+ T 
cells (Panels A-B-C-D-E) were analyzed in peripheral blood mononuclear cells (PBMCs) from healthy controls (HC; n=15), 
treatment naive MS patients (n=5), betaferon treated MS patients (n=15) and MS patients before starting Fingolimod (FTY; 
0M, n=20) and after 12M Fingolimod therapy (FTY; 12M, n=16) by flow cytometry. Histogram ﬁgures represent 
mean±S.E.M. *p <0.05, **p <0.01, ***p < 0.0001. 
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Figure 4. Fingolimod therapy alters the frequency of cytokine producing CD8+ T cell subsets. Percentages of IFN-γ, IL17, 
IL4, IL10 and IFN-γ/IL17 cytokine producing CD8+ T cells in MS patients before starting Fingolimod (Baseline) and 12 
months after Fingolimod therapy (12M). Histogram ﬁgures represent mean ±S.E.M. *p < 0.05, **p < 0.01. 
 
 
 
Figure. 5 The frequency of cytokine producing CD8+ T cell subsets in MS patients and HCs. Percentages of IFN-γ (Tc1), IL4 
(Tc2), IL17 (Tc17), IL10 (Tc10) producing and IFN-γ/IL17 co-producing CD8+ T cells (Panels A_B_C_D_E) were analyzed 
in PBMCs of healthy controls (HC; n=15), treatment naive MS patients (n=5), betaferon treated MS patients (n=15) and MS 
patients before Fingolimod therapy (FTY 0M: n=20) and after 12M Fingolimod therapy (FTY 12M; n=16) by flow cytometry. 
Histogram ﬁgures represent mean±S.E.M. *p < 0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure. 6 (A) Fingolimod therapy reduces the expression level of transcription factor IRF-4. Fingolimod treated patients had 
the lower expression level after 12M therapy compared with baseline. (B) The expression level of IRF-4 in Fingolimod-treated 
patients and other groups. HCs had the lowest mRNA levels and mRNA levels increased in treatment-naïve and MS patients 
before Fingolimod therapy. Scatter dot plots show relative mRNA expression levels analyzed by Realtime-PCR. Horizontal 
lines represent the Mean value in all subgroups. *p<0.05, **p<0.01, ***p<0.0001. 
 
 
 
 
 
 
 
 
Figure 7. (A) 17+ T cells differentiating cytokines changed in fingolimod-treated multiple sclerosis (MS) patients 
after therapy. Fingolimod treated patients had an increase in IL-6, while the increase in TGF-β1 and IL-23 did 
not reach signiﬁcance. Histogram ﬁgures represent mean ±S.E.M. (*p<0.05. 
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Figure 7. (B) Production of 17+ T cell differentiating cytokines in Fingolimod-treated patients and other groups. Production 
of IL-6, IL-23 and TGF-β1 cytokines in anti-CD3/CD28 activated peripheral blood mononuclear cells (PBMCs) of 
Fingolimod-treated patients after 12 M therapy and other groups. Histogram ﬁgures represent mean±S.E.M. *p<0.05.  
 
 
 
 
 
 
DISCUSSION 
 
Multiple sclerosis is an inflammatory disorder of 
the central nervous system mediated by an autoimmune 
T cell response against myelin antigens. Besides Th1 
and Th17 cells, recent data demonstrated that Tc17 
cells are also implicated in MS immuno 
pathogenesis.
15-17
 Among immunomodulatory drugs for 
MS treatment, Fingolimod is the only oral drug which 
efficiently reduces MS relapses by inhibiting CD4+ and 
CD8+ T cells egress from lymph nodes resulting in a 
marked lymphopenia in the peripheral blood.
40-42
 
In this 12M follow-up study, we determined the 
effect of Fingolimod on the frequency of different 
cytokine-producing CD4+ and CD8+ T cell subsets. 
Consistent with other studies,
29,40,43
 we also found 
decreased percentages of both CD4+ and CD8+ T 
lymphocytes in the peripheral blood of MS patients 
with a predominant reduction in the CD4+ T cells. 
Accordingly, CD4+/CD8+ T cell ratio decreased in 
peripheral blood as well.  
Our data showed that the frequency of IL-17 and 
IFN-γ producing CD4+ T cells were reduced in 
Fingolimod-treated patients after 12M therapy 
compared to those of control groups. These results are 
in line with the study of Mehling et al.
30
 They showed 
that FTY720 reduced the number of IL17+ CD4+ TCM 
cells, in peripheral blood of MS patients. However,  a 
recent study by Song et al.,
33
 showed that the 
percentages of both CD4+ and CD8+ IFN-γ producing 
T cells and Th17 cells increased transiently in the 2 
weeks after initiation of therapy and decreased 
gradually to the pre-treatment levels which is 
compatible with Sato et al. 's studies.
37
 They had 
explained that this increase might be due to a relative 
increase in TEM cells in pre-treatment stage, but after 
that, they are limited because of the absence of Th1 and 
Th17 replacement by naïve T cells which were trapped 
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in lymph nodes.  
Interestingly, we found a higher frequency of IL-10 
producing CD4+ T cells in Fingolimod-treated patients 
after 12M therapy in comparison with baseline. The 
reduction of Th1 and Th17 cells and higher frequency 
of Th10 cells could be the mechanism by which the 
drug alleviates the disease progression in MS. 
In the present study, we assessed the frequency of 
different cytokine producing CD8+ T cell populations. 
Our data showed that frequency of IFN-γ+ and IL-17+, 
as well as IFN-γ/IL-17 co-producing CD8+ T cells, 
decreased markedly in Fingolimod-treated patients 
after 12M, while the percentages of IL-4+ and IL-10+ 
CD8+ T cells did not differ between MS patients before 
and after 12M therapy. Consistent with our results, 
Serpero et al.
36
 observed a significant decrease in IFN-γ 
producing CD8+ T cells in Fingolimod-treated patients 
after 1M. However, in their experiments, the reduction 
of IL-17 producing T cells alone or in combination 
with IFN-γ was not statistically significant. Song et al. 
reported that the percentage of IFN-γ producing CD8+ 
T cells increased transiently at 2 weeks after initiation 
of Fingolimod and then decreased to the pre-treatment 
levels.
33
 They also revealed that IFN-γ and IL-4 
producing CD8+ T cells increased in MS patients pre-
treated with Fingolimod compared to healthy controls 
which is partly similar to our work.
33
 Tc17 cells have 
been found among infiltrating cells in MS active 
lesions and peripheral blood of RRMS patients in 
relapse phase.
15-18
 A decrease in frequency of Tc1 and 
Tc17 cells as well as IFN-γ/IL17 cytokine co-
producing CD8+ T cells, support the clinical benefits of 
Fingolimod treatment in MS disease. 
In our study, the percentage of Tc1 cells decreased 
in Betaferon treated compared to treatment naive MS 
patients, while Tc17 cells increased in the blood of 
these patients compared to healthy controls. However, 
Peelen et al. showed lower Tc1 cell percentage, but no 
difference in Tc2, Tc10 or Tc17 cell frequencies in 
Betaferon treated compared to treatment naive MS 
patients.
44
 The difference between the studies may be 
due to patient selection criteria.  
The present study, for the first time, showed 
reduced transcript levels of transcription factor IRF-4 
in Fingolimod-treated patients after therapy compared 
to baseline and treatment naive MS patients. In addition 
to the induction of RORγt and activation of STAT3 in 
the differentiation of Th17 cells, it has now revealed 
that transcription factor IRF-4 also can acts as a 
molecular activator of IL17 induction by cooperating 
with other factors.
19
  
In previous results, patients treated with Fingolimod 
experienced profound lymphopenia in the peripheral 
blood, especially for memory T cells. Since IRF4 is 
preferentially expressed in memory T cells,
45
 the 
present observation of a decreased expression of IRF4 
in PBMC of Fingolimod-treated patients is probably a 
direct consequence of the decreased number of memory 
T cells in the circulation. Recent investigations in 
several autoimmune disease models indicated the 
essential role of IRF4 in the development of pathogenic 
Th17 cells. IRF4-deﬁcient mice were protected from 
induction of EAE which is correlated with lack of Th17 
differentiation.
20
 Moreover, it was proposed that IRF4 
has a role in effector CTL response and clearance of 
intracellular pathogens.
45-47
 IRF4-deficient mice failed 
to produce CD8+ T cell-mediated immune responses 
during viral or bacterial infection.
45
 These findings 
suggest that Fingolimod through decreased expression 
of transcription factor IRF-4 may prevent the 
development of pathogenic T cells.  
According to our knowledge, few studies have 
investigated the production of pro-inflammatory 
cytokines in T cells from Fingolimod treated MS 
patients. In this respect, we evaluated the levels of 
differentiating cytokines related to IL17+ T cells. Our 
results showed that the level of IL6 significantly 
increased in Fingolimod treated patients after 12M 
therapy compared to baseline. A recent study by 
Blumenfeld et al.,
32
 indicated that production of IL-6 
and IL-10 from stimulated B cells significantly 
increased after 3 months of ﬁ indicat therapy.  
IL-6 is a pleiotropic cytokine that is present during 
inflammation and contributes to host defense.
48
 We 
propose that an increase of this cytokine in Fingolimod 
treated patients may exert its effects in the host defense 
response by stimulating other cells in Fingolimod-
treated patients. IL-6 is considered as a double-edged 
sword mediator because of both pro-inflammatory and 
potential neuroprotective functions. The elevated levels 
of IL-6 were seen in the serum of MS patients and were 
found to be significantly correlated with the number of 
relapses in MS patients.
49,50
 
In this study, the levels of TGF-β1 was high in 
Fingolimod-treated, and betaferon treated MS patients 
compared to healthy individuals. However, the increase 
in the TGF-β1 and IL23 did not reach significance in 
Fingolimod treated patients compared to baseline. 
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TGF-β is a regulatory cytokine which contributes to the 
differentiation of regulatory T cells (Tregs) and could 
ameliorate autoimmune disease.
51
 On the other hand, it 
is well established that differentiation of IL17 
producing T cells requires TGF-β cytokine which 
represents the pro-inflammatory role of this cytokine.
52
 
A recent study showed an increase of TGF-β during the 
remission phase of MS, pointing out this cytokine may 
be a good option in the treatment of MS.
18
 
We have shown that Fingolimod-treated MS 
patients after 12-Months have reduced pro-
inflammatory T cell subsets in the peripheral blood, 
including IL-17 and IFN-γ producing CD4+ T cells and 
IFN-γ+ and IL-17+ as well as IFN-γ/IL-17 co-
producing CD8+ T cells. Fingolimod increased the 
frequency of IL-10 producing CD4+ T cells as well. 
This study for the first time has demonstrated the 
reduced level of transcription factor IRF-4 in MS 
patients after Fingolimod treatment.  
These changes in T cell subsets, along with reduced 
expression of IRF-4, represents beneficial effects of 
this drug and may prevent the development of 
pathogenic T cells. However, these beneficial effects 
accompany some potential complications in MS 
patients concerning the immune response. While there 
is a decrease in relapses and progress of disease, on the 
other hand, patients have reduced CD4+ and CD8+ T 
lymphocyte in the peripheral Blood, which may affect 
the cellular immune response especially in controlling 
viral infections in long-term therapy. However, the 
remaining lymphocytes in the periphery have the 
potential to activate and secrete more IL-6 cytokine that 
helps immune defense in Fingolimod-treated MS 
patients.  
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